Wikipedia talk:WikiProject Pharmacology

Regarding the "Drug Class" info section in ChemBox

Hello there,

I had already made a post on the Wikipedia talk:WikiProject Pharmacology/Style guide page, but given that that page seems to be far less trafficked than this one, I figure I should reproduce it here. The original post is reproduce below.

---

Is there a prescribed/preferred formatting style for the "Drug Class" section found in ChembBox? I've noticed that some articles on prescription drugs spell out the class name fully (e.g. Duloxetine) where as others use just the abbreviation (e.g. Bupropion). I did a brief search in the style manual but didn't see anything prescriptive.

If no such style rule exists, might I suggest standardizing on spelling out the drug class name, capitalizing the first letter of each word, and then including the abbreviation in parenthesis afterwards? The class name should also link to the appropriate article for said class, even if it doesn't yet exist. For example, in the Duloxitine article mentioned above, the Drug Class section would say:

Drug class | Serotonin–Norepinephrine Reuptake Inhibitor (SNRI)

Similarly, for the Bupropion article, it'd be:

Drug class | Norepinephrine–Dopamine Reuptake Inhibitor (NDRI)

This seems to match how the drug class articles themselves are formatted, and it makes the most sense to me.

- ThatdeafITGuy (talk) 02:44, 13 July 2025 (UTC)

Thanks for your post. Just to clarify, I am assuming that you are referring to the |class= parameter of {{Infobox drug}} template. What you are proposing sounds reasonable. However, drug classes often do not have standard abbreviations, but including one, if it exists, is certainly reasonable. Here is a list drug class articles that can be linked to. While we have Category:Drug classes defined by psychological effects, amazingly we do not have a Category Drug classes. The later should probably be created. Boghog (talk) 08:51, 13 July 2025 (UTC)

I now see we have a Category:Drugs by mechanism of action which partially overlaps with Category Drug classes. Boghog (talk) 09:23, 13 July 2025 (UTC)

Proposed renaming of category "Anabolic-Androgenic Steroids" to Category:Androgens

I proposed renaming of Category:Anabolic–androgenic steroids to Category:Androgens. See discussion here: Categories for discussion, 2025 July 18, renaming of category "Anabolic-Androgenic Steroids" to Category:Androgens. Notifying this wikiproject, so that the renaming admins can get more opinions/approval from wikipedians interested in pharmacology. HertzDonuts (talk) 19:07, 21 July 2025 (UTC)

Have commented here and support this move. Thanks for proposing it. – AlyInWikiWonderland (talk, contribs) 07:54, 27 July 2025 (UTC)

Requested move at Talk:Pleiotropy (drugs)#Requested move 19 July 2025

There is a requested move discussion at Talk:Pleiotropy (drugs)#Requested move 19 July 2025 that may be of interest to members of this WikiProject. TarnishedPath^talk 08:28, 26 July 2025 (UTC)

Alclometasone dipropionate

Please add reliable sources to this stub. Bearian (talk) 20:51, 29 July 2025 (UTC)

AI written Event-drive pharmacology: expert needed

The recently created page Event-driven pharmacology appears to be LLM written. While there are no obvious DOI errors, it needs an expert check that the claims in the article are really supported by the sources. Ldm1954 (talk) 10:17, 3 October 2025 (UTC)

This article has a bigger issue than just appearing LLM-written. Event-driven pharmacology usually refers to the mechanism of PROTACs, where transient binding to a target protein leads to its degradation, resulting in a long-lasting effect because the protein is removed. It is less often used in the neuroscience field. Not sure how to handle this. Boghog (talk) 14:23, 3 October 2025 (UTC)

Maybe we should rename Event-driven pharmacology to event/occupancy-driven pharmacology to include protein degraders and event-driven neuropharmacology drugs. Boghog (talk) 15:37, 3 October 2025 (UTC)

I just saw this after responding to a post about it at WT:NEURO. I hadn't heard about PROTACS before, but I think this may be a false creation as to neuropharmacol. --Tryptofish (talk) 22:04, 3 October 2025 (UTC)

As suggested at WT:NEURO, one solution is to expand the scope of Chimeric small molecule therapeutics to Targeted protein degradation (TPD), and convert Event-driven pharmacology into a redirect to the new Targeted protein degradation article. Boghog (talk) 04:01, 4 October 2025 (UTC)